OPEN MINUTES
Missouri Board of Pharmacy

October 26-27, 2016
Holiday Garden Inn
3300 Vandiver, Drive
Columbia, MO

The Missouri Board of Pharmacy met in open session during the times and dates stated in the following minutes. The regular meeting was called to order by President Christina Lindsay at approximately 8:02 AM on October 26, 2016, at Holiday Garden Inn, Columbia, Missouri. Each item in the minutes is listed in the order discussed.

Board Members Present
Christina Lindsay, R.Ph., President
Christian Tadrus, R.Ph., Vice-President
Barbara Bilek, PharmD., Member
Douglas R. Lang, R.Ph., Member
Pamela Marshall, R.Ph., Member
Anita Parran, Public Member

Staff Present
Kimberly Grinston, Executive Director
Tom Glenski, R.Ph., Chief Inspector
Bennie Dean, R.Ph., Inspector
Katie DeBold, R.Ph., Inspector
Joe Dino, R.Ph., Inspector
Alicia Edmonson, Compliance Coordinator
Jennifer Luebert, Administrative Coordinator
Andi Miller, PharmD, Inspector
Lisa Thompson, R.Ph., Inspector
Dan Vandersand, R.Ph., Inspector
Elaina Wolzak, R.Ph., Inspector
Barbara Wood, R.Ph., Inspector

Others Present
Curtis Thompson, Legal Counsel

PRESIDENT LINDSAY CALLED THE OPEN SESSION MEETING TO ORDER AT APPROXIMATELY 8:02 AM

MOTION TO CLOSE 8:02 AM
At 8:02 AM, Pamela Marshall made a motion, seconded by Christian Tadrus, that the Board go into closed session and that all votes, to the extent permitted by law, pertaining to and/or resulting from this closed meeting be closed under Section 610.021(1), (3), (5),
(7), (13), (14), (17) and (20), RSMo, and under Section 324.001.8, and .9, RSMo. Motion passed 5:0:0:0 with roll call vote as follows:

Barbara Bilek – yes Pamela Marshall – yes Anita Parran – yes
Douglas Lang – yes Christian Tadrus – yes

MEMBERS OF THE PUBLIC LEFT THE MEETING ROOM AT 8:03 AM

RETURN TO OPEN
By motion duly made, seconded, passed and recorded in closed session minutes, the Board returned to open session at approximately 9:12 AM.

MEMBERS OF THE PUBLIC ENTERED THE MEETING ROOM AT 9:13 AM

PRESIDENT LINDSAY CALLED THE OPEN SESSION MEETING TO ORDER AT APPROXIMATELY 9:23 AM

President Lindsay indicated the rule review noted in the agenda will begin at approximately 1:00 p.m.; Mrs. Lindsay noted comments would be limited to two (2) minutes per speaker to accommodate all attendees. Mrs. Lindsay further noted the Board will accept written public comments for an additional thirty (30) days.

#A1 Agenda Additions/Corrections

No agenda additions/corrections reported, however, additional review items were included in the E section of the agenda for informational purposes.

#A2 Board Member Report

DISCUSSION: Board members reported on the following:

- Pamela Marshall and Douglas Lang reported on NABP’s District 6, 7 and 8 annual meeting held in Portland, Oregon. Mrs. Marshall indicated the meeting was informative and included several timely presentations such as expansion of technician duties and biosimilar regulation. Mr. Lang noted an informative session was presented on specialty pharmacy.

- Douglas Lang reported on the FDA’s recent 50-state meeting held in Silver Springs, Maryland, to discuss state/federal regulation of sterile compounding and drug outsourcers. Mr. Lang reported FDA indicated it would be inspecting pharmacies for compliance with JSP Chapter 797 more than cGMP requirements. Mr. Lang noted the FDA once again focused on insanitary pharmacy conditions and noted there were several state presentations on pharmacy oversight as well as smaller group discussions on FDA regulatory issues and proposed guidance. Barbara Bilek asked if FDA addressed compounding for office use; Douglas Lang and Kimberly Grinston reported the FDA appeared to clearly establish that compounding for office use by a pharmacy is prohibited. Mrs. Grinston indicated the FDA discussed a proposed 1-mile radius that would allow hospitals to distribute non-patient specific compounds for use in hospital related facilities, however, no final FDA determination has been made.
Christina Lindsay reported on the September 2016 meeting of the Pharmacy Technician Working Group. Mrs. Lindsay noted the initial meeting was focused on establishing technician classifications and identifying allowed tasks/scope of practice for each class. The next meeting is scheduled for December of 2016 and will include presentations from ExCPT and PTCB and a discussion of qualifications for each classification.

Douglas Lang reported he has been appointed to NABP’s telepharmacy task force that will be reviewing the current model rule and suggesting revisions. Mr. Lang noted the initial meeting included a presentation from North Dakota on their telepharmacy model and its impact on pharmacy jobs. Mr. Lang suggested discussing this topic at the next strategic planning meeting and recommended the Board discuss the use of telepharmacy in a variety of practice settings.

#A3 General Administration Report

DISCUSSION: Kimberly Grinston provided the following updates:

- **Financial Report:** Mrs. Grinston reported revenue continues to trend upward. Reduced renewal fees will be effective for pharmacists and interns renewing in 2016 and technicians renewing in 2017. Mrs. Grinston noted the Board’s previous legislative proposal that would allow the Board to expend funds to prevent/address prescription drug abuse may be introduced again this year which would decrease the excess fund balance.

- **2016 Legislative Implementation:** The Board received positive feedback on the legislative implementation material provided to licensees; No implementation issues have been identified.

- **2017 Legislation:** The process for approving 2017 legislative proposals is still unclear given the pending change of administration. Budget requests are being reviewed by the current Office of Administration. Additional updates will be provided once received.

- **General Office Updates:** The office is experiencing high volume given the ongoing pharmacist and intern renewals. Mrs. Grinston commended Amber Cundiff on her prompt processing of new pharmacist applications. The pharmacist renewal rate appears to be relatively high which may be attributed to the reduced pharmacist renewal fee.

- **Rule Updates:** The final amended sterile compounding rule will be effective shortly. The Collection of Non-Controlled Medication for Destruction rule is open for public comment through October 30th; comments will be provided to the Board on the November conference call.

- **Joint Patient Safety Conference:** The Board hosted the conference in October with Missouri’s other healthcare licensing boards. Approximately 420 people registered with 380-390 actually attending. Significant discussion was held on prescription drug abuse/misuse. A pharmacist speaker was scheduled but unable to attend. Board members asked how the office could better advertise the program and suggested possibly hosting the program earlier in the year.

- **Kansas City Diversion Conference:** After consultation with President Lindsay, the Kansas City conference was postponed due to low enrollment. Approximately 44 people registered,
including, 4-5 staff members. Mrs. Grinston reported other boards reported issues with low enrollment in the Kansas City area. The Board discussed possibly hosting a program in Springfield. Board consensus to reschedule the Kansas City conference for 2017 and to work on enhanced ways to advertise. Doug Lang suggested asking the DEA to present the scheduled corresponding responsibility session as a Board webinar.

- **Holiday Lunch**: The winter inspector training and staff holiday lunch is scheduled for 12/15/16. Board members are welcome to attend.
- **NABP Executive Officers Meeting**: Mrs. Grinston attended the Executive Officers meeting held in Chicago. Mrs. Grinston reported interesting discussions were held on accommodating out-of-state prescribers and state initiatives on pharmacist prescribing. A major topic of discussion was the recent NAPLEX/MPJE passing rates which most states indicated declined significantly. One NABP district estimated a 64% decrease in pass rates. NABP is investigating the decline and noted a decrease would normally be expected after a change in the exam which occurred in 2016. Mrs. Grinston also reported other states expressed concerns with regulation of hospital pharmacy practice and noted several states expressed concerns that Joint Commission and CMS standards may not be sufficient to protect the public.

**#B1 Susan Holly Baker, #042267, 8650 Girl Scout Rd, Pevely, MO 63070, #2013-006080**

**ITEMS ENCLOSED:**
- Notice of Disciplinary Hearing
- Stipulation For Cause To Discipline
- Administrative Hearing Commission Consent Order

**DISCUSSION:** The Board convened a disciplinary hearing at 10:27 AM Alicia Turner-Embley was present as counsel for the Board. Johnny Richardson was present on behalf of Mrs. Baker who was also in attendance. Mrs. Turner and Mr. Richardson provided opening statements. Exhibits and witnesses were presented. Mrs. Turner and Mr. Richardson provided closing statements. The hearing adjourned at 11:38 AM A transcript of the hearing is available in the Board’s records.

**VICE-PRESIDENT CHRISTIAN TADRUS LEFT THE MEETING ROOM.**

**#A2 Approval of Minutes**
- April 5, 2016 Open Session
- May 11, 2016 Conference Call
- June 15, 2016 Conference Call
- July 19, 2016 Strategic Planning
- July 20, 2016 Open Session

**DISCUSSION:** Douglas Lang noted Christian Tadrus should be designated as Vice-President. A motion was made by Pamela Marshall, seconded by Barbara Bilek, to approve the April 2016 minutes as printed with the recommended change. Motion passed 3:0:1:1 by roll call vote as follows:
Anita Parran – abstain

DISCUSSION: A motion was made by Douglas Lang, seconded by Barbara Bilek, to approve the May 2016 minutes as printed. Motion passed 4:0:0:1 by roll call vote as follows:

Anita Parran – yes

DISCUSSION: A motion was made by Douglas Lang, seconded by Pamela Marshall, to approve the June 2016 minutes as printed. Motion passed 4:0:0:1 by roll call vote as follows:

Anita Parran – yes

VICE-PRESIDENT TADRUS RETURNED TO THE MEETING.

DISCUSSION: A motion was made by Pamela Marshall, seconded by Barbara Bilek, to approve the July 2016 Strategic Planning minutes as printed. Motion passed 5:0:0:0 by roll call vote as follows:

Anita Parran – yes

DISCUSSION: A motion was made by Douglas Lang, seconded by Pamela Marshall, to approve the July 20-21, 2016 minutes as printed. Motion passed 4:0:1:0 by roll call vote as follows:

Anita Parran – yes

#A5 Inspection/Investigation Update (Tom Glenski, Chief Inspector)
- General inspection/investigation update
- Current inspection/investigation statistics
- Compliance issues and trends
- Sterile compounding rule implementation
- Upcoming LWTC Webinars/Training
- DHSS Training opportunity

DISCUSSION: Chief Inspector Tom Glenski provided the following inspection/investigation updates:
- A higher number of complaints were opened in September 2016 which may result in a larger volume of inspection reports in January.
- Mr. Glenski presented the inspection/investigation summary and noted no major changes or new trends are apparent. Mr. Glenski commented the Board will likely see more expired
technician and immunization cases given the recent technician renewal period and the upcoming flu season.

- The Board received positive feedback on its educational campaign on the revised sterile compounding rule. As part of the campaign, staff hosted three (3) webinars in addition to issuing the implementation guide. Over twenty (20) sterile compounding pharmacies have been inspected since the emergency rule was promulgated. Any new rule requirements are being noted as comments and not as official violations at this time.
- The October 2016 webinar was originally intended to be a follow-up to the Kansas City diversion conference. The webinar was cancelled in light of the postponed conference and will likely be offered in 2017.
- Board inspectors attended an interview training program hosted by the Division which included approximately 36 investigators from various boards. Katie DeBold also hosted a two-day sterile compounding training program for Board inspectors at St. Louis College of Pharmacy that included hands-on training. The office may host the sterile compounding training annually.
- Two (2) inspectors have completed Critical Point's sterile compounding training program for regulators which is now a combined USP Chapter 797 and Chapter 800 training program. The current goal is to have all inspectors complete Critical Point training.
- Katie DeBold and Tom Glenski will be providing sterile compounding training for Missouri's DHSS inspectors.

#C1 Applications for Intern Training Special Site/Non-Pharmacist Preceptor
- Medication Management Resolution
- SSM Health

DISCUSSION: Tom Glenski recommended approval of the special sites/non-pharmacist preceptors presented. A motion was made by Douglas Lang, seconded by Christian Tadrus, to approve all Intern Training Special Site/Non-Pharmacist Applications for 500 hours. Motion passed 5:0:0:0 with roll call vote as follows:
  Anita Parran – yes    Christian Tadrus – yes

#C2 STLCOP and UMKC College of Pharmacy

DISCUSSION: No site/preceptor lists were submitted for approval.

#D12 REVIEW OF NAPLEX/MPJE PASS RATES
- NABP July 28, 2016 Memo re: NAPLEX Changes
- NABP September 8, 2016 Memo re: NAPLEX waiting periods
- Missouri MPJE Statistical Data

DISCUSSION: Kimberly Grinston reported NABP has indicated the national pass rate for both the NAPLEX and state MPJE examinations has declined. Board members expressed concerns and asked about NABP's efforts to identify the cause. Mrs. Grinston reported Carmen Catizone asked if
the states should look at school admission policies to determine if pharmacy schools are admitting students who may not be able to pass the national exam.

Kimberly Grinston reported testing information for Missouri’s pharmacy schools were provided in the Board's handouts; Mrs. Grinston noted both Missouri schools experienced a sharp decrease in pass rates. Due to the high number of re-testers, Mrs. Grinston reported waiving NABP’s recommended 90-day retest period and authorizing students to retest as early as 45-days after the previous exam. Mrs. Grinston reported the American Association of Colleges of Pharmacy has reportedly formed a task force to conduct its own study.

Public attendee Samuel Leveritt noted exam questions were increased by 30% and asked if more research is needed on the actual exam. Mrs. Grinston reported NABP informed states that it has a rigorous process for vetting exam questions and has previously indicated NAPLEX questions are reviewed by 80 different people before a question enters the exam pool. Mrs. Grinston also expressed concerns that the new question format may be impacting student results. Board consensus to continue to monitor exam rates and any future NABP developments.

#D1  FDA DQSA Guidance/Implementation
- FDA September 2016 Inter-Governmental Meeting Update
- 21 CFR—Part 216 (Compounding of Drug Products Withdrawn or Removed From The Market)
- FDA Guidance (Insanitary Conditions at Compounding Facilities)

DISCUSSION: Mrs. Grinston reported these items have been provided for informational purposes. No additional Board discussion was held.

#D2  Review of 20 CSR 2220-6.040
- Rule Review Calendar
- Section 536.175 (Rule Review Statute)
- 20 CSR 2220-6.040 (Administration by Medical Prescription Order)
- Hospital Advisory Committee Comments

DISCUSSION: Christina Lindsay opened the floor for discussion of the current rule. The following discussion was held:
- Bert McClary, Chairman of the Hospital Advisory Committee (HAC), provided the Committee has been working on revisions to this rule for several years. Mr. McClary noted the rule was primarily written for community pharmacy and needs to be revised to better accommodate pharmacists in hospital/health systems that may be operating under the Board's jurisdiction. Mr. McClary noted the changes included in the agenda include both staff changes and the Committee's changes.
- Douglas Lang asked about the recommended removal of the prohibition on licensees administering while on discipline. Mrs. Grinston indicated the Board previously asked to amend this provision to grant the Board discretion.
- Pamela Marshell asked if the rule should address any future expansion of technician duties. Mrs. Grinston suggested amending the rule to provide "Except as otherwise provided by law," to accommodate future rule/legislative changes.

- Barbara Bilek asked if the rule should require or allow reporting to ShowMe Vax in addition to, or in lieu of, the currently required notifications. Board discussion was held. Kimberly Grinston recommended the Board consult with legal counsel in closed session to discuss statutory authority.

- Douglas Lang expressed concerns with removing the requirement that pharmacists document the lot number. Mr. Lang specifically questioned how patient notifications would be handled in the event of a recall. Christian Tadrus noted retail pharmacies may not routinely track lot numbers now. Bert McClary and public attendee David Wolfrath noted hospitals may not track lot numbers for all medication. Mr. Lang noted the federal track and trace requirements may require lot number documentation.

- Douglas Lang suggested omitting section (10). Samuel Leveritt asked if section (5)(E) should reference the amount of time a patient should be asked to stay for observation after a vaccine is given.

- Further Board discussion was held. Board consensus to consult with legal counsel and to revise the draft in light of the comments received.

#D3 Review of 20 CSR 2220-6.050

- 20 CSR 2220-6.050 (Administration of Vaccines Per Protocol)
- Walgreens Comments
- Wal-Mart Comments

DISCUSSION: Christina Lindsay opened the floor for discussion of the current rule. The following discussion was held:

- Tomson George from Walgreens commented the protocol process is lengthy and noted it could take weeks for a new protocol to be initiated or amended. Mr. George provided the following specific suggestions on behalf of Walgreens:
  1. Remove the 50-mile radius requirement
  2. Remove the requirement for individual protocol signatures and instead allow the pharmacist-in-charge to sign on behalf of the pharmacy
  3. Remove unnecessary protocol requirements and instead require written pharmacy policies and procedures that must be available on inspection
  4. Align the notification of intent renewal requirements to coincide with pharmacist license renewals, and
  5. Revise the current notification requirements to allow other forms of notification. Mr. George reported notification may be duplicated if the pharmacy is also reporting to Missouri's immunization registry.

- Board discussion was held. Christian Tadrus asked if the Board will encounter challenges with the Board of Healing Arts (BOHA) on removing the 50-mile rule. Mrs. Grinston reported BOHA previously approved removing the 50-mile requirement for MTS but noted BOHA has been historically resistant to removing the requirement in the immunization rule. Christian Tadrus suggested amending the rule to better accommodate electronic notifications or to allow notification as required by the governing protocol.
- Board consensus to have staff revise the rule in light of the public comments and to review draft revisions at a future meeting.

#D4 Review of 20 CSR 2220-6.055
- 20 CSR 2220-6.055 (Current Rule)

**DISCUSSION:** Christina Lindsay opened the floor for discussion of the rule. The following discussion was held:
- Christina Lindsay asked if consideration of the rule should be postponed pending completion of the Pharmacy Technician Working Group’s suggestions.
- Douglas Lang asked if the rule should address ordering and performing lab tests. Barbara Bilek noted hospital pharmacists have been ordering and performing lab tests for years and suggested Missouri law should recognize current practice. Kimberly Grinston noted a legislative change may be required and cautioned that physician advocacy groups have strongly resisted the suggestion of pharmacists being able to diagnose based on lab results. Board consensus to consult with legal counsel.

#D5 Review of 20 CSR 2220-2.650
- 20 CSR 2220-2.650 (Standards of Operation for a Class J: Shared Services Pharmacy)
- 2015 Draft Proposed Rule

**DISCUSSION:** Christina Lindsay opened the floor for discussion of the current rule. The following discussion was held:
- Christian Tadrus noted technology has significantly impacted shared service arrangements. Mr. Tadrus suggested the Board look at undefined rule terms and review the rule’s applicability to specialty practice.
- Additional board discussion was held. Douglas Lang asked for a comparison draft of the current rule and the 2015 draft proposed rule. Board consensus to have staff update current suggestions and return the rule for review at a future meeting.

#D6 Review of Strategic Planning Report
- AHC Consulting, LLC Strategic Planning Report
- Board 2017 Strategic Plan/Goals

**DISCUSSION:** Kimberly Grinston presented the final strategic planning report from AHC Consulting, LLC. Board discussion was held on next steps. Board consensus to ask AHC Consulting to assist the Board with developing specific and measurable goals based on the submitted report. Board members asked staff to research meeting with AHC Consulting in February to formalize an action plan.

#D7 2016 NIOSH HAZARDOUS DRUGS LIST
- NIOSH List of Antineoplastic and Other Hazardous Drugs in Health Settings, 2016

**DISCUSSION:** Mrs. Grinston reported the agenda materials were provided for informational purposes. No additional Board discussion was held.
**#D8 JOINT LETTER ON USP CHAPTER 800**
- September 16, 2016 Correspondence from:
  - American Pharmacists Association (APhA)
  - American Society of Consultant Pharmacists (ASCP)
  - College of Psychiatric and Neurologic Pharmacists (CPNP)
  - International Academy of Compounding Pharmacists (IACP)
  - National Alliance of State Pharmacy Associations (NASPA)
  - National Association of Chain Drug Stores (NACDS)
  - National Community Pharmacists Association (NCPA)

**DISCUSSION:** Christian Tadrus suggested the Board take no action on implementing USP Chapter 800 at this time given the complexity of the issue and widespread concerns. Barbara Bilek commented the new requirements may have significant financial impact on licensees and cautioned against the Board moving too quickly. Douglas Lang asked how other states are addressing this issue. Kimberly Grinston reported some states are providing education, other states are moving towards active enforcement while other states have agreed to delay enforcement. Board consensus to take no action at this time but monitor future developments.

**#D9 Hospital Advisory Committee Update**
- June 3, 2016 Agenda
- June 3, 2016 Minutes
- July 15, 2016 Agenda
- August 26, 2016 Agenda
- September 28, 2016 Agenda

**DISCUSSION:** Chairman Bert McClary provided the following updates:
- The Committee has been working on the Class-B guidance document included in the Board’s agenda and would like the Board to approve/address the specific areas highlighted.
- The Committee will be looking at a potential Class-B rule that would address a variety of issues, including, Class-B distribution, labeling and administration.
- The Committee is still asking for guidance on the applicability of the Board’s medication therapy services rule within a licensed hospital. The Committee will also be considering a suggested draft rule that would allow hospital pharmacies to stock and be responsible for medication in non-licensed health system areas (e.g., infusion clinics).
- The Committee has postponed discussion of technician duties in light of the Pharmacy Technician Working Group’s activities. At some point, the Committee would like to address advanced technician roles.

**#D10 Class-B Pharmacy Guidance**
- Class-B Pharmacy Draft Guidance Document

**DISCUSSION:** Kimberly Grinston presented the guidance document for Board discussion. The following discussion was held:
• Douglas Lang expressed concerns regarding the amended labeling allowance and asked how medication would be labeled if sent home with the patient. Mr. Lang commented patients would need to have all necessary information in the event of an emergency. Public Attendee James Gray expressed hospitals may not have the technical capabilities to generate two (2) different labels and noted detailed medication information is provided to the patient with the discharge instructions. Mr. Gray noted multiple agencies regulate the accuracy and adequacy of discharge instructions and stated patients are generally given contact information for the hospital. Bert McClary noted DHSS has a rule that addresses medication labeling, including, labeling for medication sent home. Mr. McClary reported pending DHSS labeling rules are similar to the draft suggestions. Additional Board discussion was held; no changes were made to the draft labeling section.

• Discussion was held regarding draft language addressing take home medications. Mrs. Grinston noted the draft language may be overly broad and could be construed to include things such as inhalers which was not the original intent. Douglas Lang commented there may be additional Board concerns if the language includes 5-FU pumps which are sterile preparations. Barbara Bilek suggested the focus should be on products that are not self-administered but are started/programmed by the nurse or doctor.

• Board consensus to revise the language in light of the comments and return the draft to the Board in November.

#D11 2016 MISSOURI PHARMACY PRACTICE GUIDE
• Draft Practice Guide (For Discussion Purposes)

DISCUSSION: Kimberly Grinston presented the guidance document for Board discussion. Christian Tadrus asked if diagnostic testing should be changed to laboratory testing. Board consensus to reference laboratory testing. Mr. Tadrus further recommended modifying p. 287 to include instances where inventory is not transferred to a licensee after a close/termination of business. Mr. Tadrus also recommended referencing the November 2013 newsletter article on emergency pharmacist dispensing to provide additional clarity.

Additional Board discussion was held. A motion was made by Christian Tadrus, seconded by Barbara Bilek, to approve the Practice Guide with the suggested amendments. Motion passed 5:0:0:0 with roll call vote as follows:
            Anita Parran – yes  Christian Tadrus – yes

Board consensus to mail the practice guide to all in-state pharmacies if financially feasible.

THE FOLLOWING ITEMS WERE REVIEWED IN SECTION E, WHICH REQUIRED NO ACTION OR DISCUSSION.

#E1 Licensees Presently Under Discipline
• Pharmacists
• Pharmacies
• Drug Distributors

Missouri Board of Pharmacy
Open Minutes
October 26-27, 2016
Page 11 of 13
- Pharmacy Technicians – Conditional Registration
- Pharmacy Technicians – Employment Disqualification List

#E2 Board Licensee Statistics

MOTION TO CLOSE
At 3:12 PM, Barbara Bilek made a motion, seconded by Anita Parran, that the Board go into closed session and that all votes, to the extent permitted by law, pertaining to and/or resulting from this closed meeting be closed under Section 610.021(1), (3), (5), (7), (13), (14) and (17), RSMo, and under Section 324.001.8, and .9, RSMo. Motion passed 5:0:0:0 with roll call vote as follows:

Anita Parran – yes  Christian Tadrus – yes

MEMBERS OF THE PUBLIC LEFT THE MEETING ROOM AT APPROXIMATELY 3:15 PM

RECONVENE OPEN 9:49 AM
THURSDAY, OCTOBER 27, 2016

By motion duly made, seconded, passed and recorded in closed session minutes, the Board returned to open session at approximately 9:49 AM on October 27, 2016.

#B2 Shannon Krieg, #200500313, #2016-001469

ITEMS ENCLOSED:
- Notice of Hearing on Violation of Disciplinary Order
- Violation Complaint

DISCUSSION: The Board convened a disciplinary hearing at 10:00 AM Cotton Wallker was present as counsel for the Board. Shannon Krieg was not present and was not represented by counsel. Exhibits and witnesses were presented. Mr. Walker provided a closing statement. The hearing adjourned at 10:15 AM. A transcript of the hearing is available in the Board’s records.

MOTION TO CLOSE
At 10:15 AM, Douglas Lang made a motion, seconded by Barbara Bilek, that the Board go into closed session and that all votes, to the extent permitted by law, pertaining to and/or resulting from this closed meeting be closed under Section 610.021(1), (3), (5), (7), (13), (14) and (17), RSMo, and under Section 324.001.8, and .9, RSMo. Motion passed 5:0:0:0 with roll call vote as follows:

Anita Parran – yes  Christian Tadrus – yes

RECONVENE OPEN 5:29 PM
THURSDAY, OCTOBER 27, 2016
By motion duly made, seconded, passed and recorded in closed session minutes, the Board returned to open session at approximately 5:29 PM on October 27, 2016.

**MOTION TO ADJOURN 5:29 PM**
At approximately 5:29 PM, a motion was made by Douglas Lang, seconded by Barbara Bilek, to adjourn the October 2016 meeting. Motion passed 3:0:0:2 with roll call vote as follows:

- Barbara Bilek – yes
- Douglas Lang – yes
- Pamela Marshall – yes
- Anita Parfan – absent
- Christina Lindsay – absent

________________________
KIMBERLY A. GRINSTON
EXECUTIVE DIRECTOR

DATE APPROVED: